Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 49.92% Upside As of ...

Vanguard Value offers an alternative to growth-heavy index funds. It also pays a respectable dividend yield. 10 stocks we ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings. 10 stocks we like ...

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

FNDA offers diversified small-cap exposure, attractive valuation versus indices, and lags VUG’s tech-heavy performance. Learn ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

Explore how differences in holdings, volatility, and sector mix set these two growth ETFs apart for portfolio construction.

MSCI may cut Strategy Inc., risking up to $9 billion in passive outflows. Bitcoin-heavy balance sheet threatens index eligibility as valuation premium collapses. January 15 ruling will define future ...